Apmonia Therapeutics
June 23, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Oncology
Apmonia Therapeutics is a clinical-stage biotechnology company developing first-in-class peptide therapeutics targeting extracellular matrix signaling and the tumor microenvironment. Our lead program, AP-01 (TAX2), targets thrombospondin-1 (TSP-1) and modulates the TSP-1/CD47 axis, a key regulator of tumor angiogenesis and immune suppression. The program has received CTA approval in Europe and is entering Phase 1/2a clinical trials in advanced solid tumors. Apmonia has also developed a proprietary peptide discovery platform generating additional oncology and cardiovascular programs. The company has secured over €20M in funding and is currently raising a Series A extension to reach clinical proof-of-concept.
Company HQ City:
Reims
Company HQ State:
Champagne
Company HQ Country:
France
Year Founded:
2019
CEO
Albin Jeanne
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}